Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study

NCT00297102 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00297102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Roflumilast on Exacerbation Rate in Patients With COPD. The AURA Study
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2006
Completion date
September 30, 2008
Enrollment
1,523 (actual)
Sites
179

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease (copd)